CME Information
Target audience
This educational activity is intended for physicians, and nurses involved in the
care of patients
with chronic constipation or IBS-C, and other healthcare professionals with an
interest in
learning more about the latest data in this field.
Learning objectives
At the conclusion of this activity, participants should be able to:
- Explain the underlying, multi-factorial mechanisms of constipation
- Recognize the value of a symptom-led differential diagnosis of chronic constipation
and
IBS-C and the optimal use of diagnostic testing
- Evaluate therapeutic options for patients with constipation.
CME/CE-certification
FOR PHYSICIANS
This Activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of CME Consultants and Strategic Consultants International. CME Consultants is accredited by the ACCME to provide continuing medical education for physicians.
CME Consultants, designates this educational activity for a maximum of 2.0 AMA PRA Category 1
Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
FOR NURSES
 |
CME Consultants, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. |
| CME Consultants designates this activity for 2.0 contact hours. Participants should claim only those contact hours actually spent in the education activity. |
| In order to receive credit for this activity, each participant must complete the evaluation and certificate request form. Certificates will be mailed to activity participants in approximately four to six weeks after receipt of the completed evaluation form and sign-in sheet. |
FOR NURSE PRACTITIONERS
This program has been approved for 2.0 contact hours of continuing education by the American Academy of Nurse Practitioners. Program ID 0801053
January 10, 2008 through January 9, 2009
Faculty disclosures
In direct response to the September 2004 Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, CME Consultants issued a conflict of interest policy dated January 2, 2005. The policy states that the disclosure of potential financial conflicts of interest within the last 12 months must be made and resolved prior to date of the CME/CE activity where commercial support grants are to be used to fund the activity. The following conflicts have been managed and resolved through CME Consultants’ Independent Review Committee. Our intent is to assist learners in assessing the potential for bias in information that is presented during this CME/CE activity.
The faculty is also aware it is their responsibility to inform the audience if discussion of any non-FDA approved uses of pharmaceuticals, medical equipment, prostheses, etc. will be included in their presentation.
| Name |
Company |
Relationship |
| Lawrence J. Brandt |
EZM, Novartis Pharmaceuticals |
Speaker / Honorarium |
| John F. Johanson |
GlaxoSmithKline, Prometheus, Salix, Sucampo Pharmaceuticals, Takeda Pharmaceuticals North America |
Speaker / Honorarium |
| Boehringer Ingelheim, Prometheus, Salix, Sucampo Pharmaceuticals, Takeda Pharmaceuticals North America, Theravance Inc. |
Consulting |
| Sucampo Pharmaceuticals, Takeda Pharmaceuticals North America |
Honorarium |
| Sucampo Pharmaceuticals |
Stock options |
| Satish S.C. Rao |
Forest Laboratories, Johnson & Johnson, Novartis Pharmaceuticals, SmartPill, Takeda Pharmaceuticals North America, Theravance Inc. |
Consultant / Advisory Board |
| AstraZeneca, Janssen, Novartis Pharmaceuticals, Salix, TAP Pharmaceuticals, Takeda Pharmaceuticals North America |
Speaker Bureau |
| SmartPill, Sucampo Pharmaceuticals, Takeda Pharmaceuticals North America |
Unrestricted grants |
| Lawrence R. Schiller |
Abbott Immunology, McNeil Pharmaceuticals, Napo Pharmaceuticals, Novartis Pharmaceuticals, Prometheus Labs, Santarus, Sucampo Pharmaceuticals, Takeda Pharmaceuticals North America, UCB Pharmaceuticals |
Advisory Board |
| Abbott Immunology, AstraZeneca, Novartis Pharmaceuticals, Prometheus Labs, Santarus, Sucampo Pharmaceuticals, Takeda Pharmaceuticals North America |
Consultant / Speaker |
The planners, managers and anyone in a position to control the content of CME activities are also required to report any conflicts of interest. The following conflicts have been managed and resolved through CME Consultants’ Independent Review Committee.
| Name of planner or manager |
Company and Relationship |
Samantha Mattiucci, PharmD CME Consultants |
Nothing to disclose |
Joyce M. Anderson, Project Director CME Consultants |
Nothing to disclose |
Ian Morgan, Project Director
Strategic Consultants International |
Nothing to disclose |
Ailsa Stewart, Senior Project Manager
Strategic Consultants International |
Nothing to disclose |
|